What survival data shows for Polivy in lymphoma treatment
Polivy (polatuzumab vedotin), approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), pairs with bendamustine and rituximab (BR). In the phase 3 POLARIX trial, it improved progression-free survival (PFS) over BR alone: median PFS was 17.8 months with Polivy-BR versus 9.8 months with BR alone, a 50% reduction in progression or death risk (HR 0.50; 95% CI 0.39-0.65).[1][2]
Overall survival (OS) data remains immature; at 28 months, no significant OS difference emerged (HR 0.86; 95% CI 0.65-1.13), though trends favor Polivy-BR.[1]
How much does Polivy extend median PFS?
Across key trials:
- POLARIX (newly diagnosed DLBCL): +8 months median PFS gain (17.8 vs 9.8 months).[1]
- Phase 2 (relapsed/refractory DLBCL): Median PFS 7.6 months with Polivy-BR vs 2.0 months historical BR data, roughly tripling PFS.[3]
No universal "average survival rate boost" exists, as gains vary by line of therapy and patient factors; PFS boosts range 5-8 months in frontline settings.
Does Polivy improve overall survival rates?
OS benefits are unproven in pivotal trials. POLARIX showed 2-year OS rates of 80.8% (Polivy-BR) vs 78.7% (BR), not statistically significant.[1] Longer follow-up continues; subgroup analyses suggest larger gains in high-risk patients (e.g., double-hit lymphoma).[2]
What about event-free survival or other endpoints?
Polivy-BR cut event-free survival (EFS) risk by 52% in POLARIX (HR 0.48), with 2-year EFS 67.6% vs 50.3%.[1] PET-complete response rates rose to 78% from 66%.[2]
Who sees the biggest survival gains from Polivy?
Frontline high-risk DLBCL patients gain most (PFS HR 0.37 in double-expressors).[2] Less benefit in low-risk or heavily pretreated cases. Real-world data mirrors trial PFS boosts but with higher neuropathy rates impacting tolerability.[4]
How does Polivy stack up against CAR-T or other regimens?
Versus CAR-T (e.g., axicabtagene ciloleucel): Polivy-BR PFS shorter (18 vs 26 months) but better tolerability and lower cost.[5] Beats R-GemOx (PFS 7.6 vs 3.7 months).[3]
[1]: New England Journal of Medicine - POLARIX Trial (2022)
[2]: FDA Approval Summary for Polivy
[3]: The Lancet Oncology - Phase 2 Polivy Data (2019)
[4]: Journal of Clinical Oncology - Real-World Polivy Outcomes (2023)
[5]: Blood - CAR-T vs Polivy Comparisons (2023)